BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

855 related articles for article (PubMed ID: 10905768)

  • 21. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
    Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
    Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation.
    Antin JH; Childs R; Filipovich AH; Giralt S; Mackinnon S; Spitzer T; Weisdorf D
    Biol Blood Marrow Transplant; 2001; 7(9):473-85. PubMed ID: 11669214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
    Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
    Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Graft-versus-host-reactive donor CD4 cells can induce T cell-mediated rejection of the donor marrow in mixed allogeneic chimeras prepared with nonmyeloablative conditioning.
    Kim YM; Mapara MY; Down JD; Johnson KW; Boisgerault F; Akiyama Y; Benichou G; Pelot M; Zhao G; Sykes M
    Blood; 2004 Jan; 103(2):732-9. PubMed ID: 14512313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
    Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
    Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stable engraftment after a conditioning regimen with fludarabine and melphalan for bone marrow transplantation from an unrelated donor.
    Inamoto Y; Oba T; Miyamura K; Terakura S; Tsujimura A; Kuwatsuka Y; Tokunaga M; Kasai M; Murata M; Naoe T; Kodera Y
    Int J Hematol; 2006 May; 83(4):356-62. PubMed ID: 16757439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia.
    Huss R; Deeg HJ; Gooley T; Bryant E; Leisenring W; Clift R; Buckner CD; Martin P; Storb R; Appelbaum FR
    Bone Marrow Transplant; 1996 Oct; 18(4):767-76. PubMed ID: 8899193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants.
    Daly A; McAfee S; Dey B; Colby C; Schulte L; Yeap B; Sackstein R; Tarbell NJ; Sachs D; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2003 Jun; 9(6):373-82. PubMed ID: 12813445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Photochemical treatment of donor lymphocytes inhibited their ability to facilitate donor engraftment or increase donor chimerism after nonmyeloablative conditioning or establishment of mixed chimerism.
    Johnson BD; Taylor PA; Stankowski MC; Talib S; Hearst JE; Blazar BR
    Biol Blood Marrow Transplant; 2002; 8(11):581-7. PubMed ID: 12463476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.
    de Lima M; Bonamino M; Vasconcelos Z; Colares M; Diamond H; Zalcberg I; Tavares R; Lerner D; Byington R; Bouzas L; da Matta J; Andrade C; Carvalho L; Pires V; Barone B; Maciel C; Tabak D
    Bone Marrow Transplant; 2001 Jan; 27(1):73-8. PubMed ID: 11244440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide for patients with hematologic malignancies.
    Nakajima H; Oki M; Kishi K; Ueyama J; Miyakoshi S; Hatsumi N; Sakura T; Miyawaki S; Yokota A; Fujisawa S; Mori S; Tanaka Y; Sakamaki H;
    Clin Lab Haematol; 2003 Dec; 25(6):383-91. PubMed ID: 14641143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiation.
    Geller RB; Devine SM; O'Toole K; Persons L; Keller J; Mauer D; Holland HK; Dix SP; Piotti M; Redei I; Connaghan G; Heffner LT; Hillyer CD; Waller EK; Winton EF; Wingard JR
    Bone Marrow Transplant; 1997 Aug; 20(3):219-25. PubMed ID: 9257890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.
    Alyea E; Weller E; Schlossman R; Canning C; Webb I; Doss D; Mauch P; Marcus K; Fisher D; Freeman A; Parikh B; Gribben J; Soiffer R; Ritz J; Anderson K
    Blood; 2001 Aug; 98(4):934-9. PubMed ID: 11493435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma.
    Rubio MT; Kim YM; Sachs T; Mapara M; Zhao G; Sykes M
    Blood; 2003 Sep; 102(6):2300-7. PubMed ID: 12791660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism.
    Spitzer TR; Delmonico F; Tolkoff-Rubin N; McAfee S; Sackstein R; Saidman S; Colby C; Sykes M; Sachs DH; Cosimi AB
    Transplantation; 1999 Aug; 68(4):480-4. PubMed ID: 10480403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia.
    Iannone R; Casella JF; Fuchs EJ; Chen AR; Jones RJ; Woolfrey A; Amylon M; Sullivan KM; Storb RF; Walters MC
    Biol Blood Marrow Transplant; 2003 Aug; 9(8):519-28. PubMed ID: 12931121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
    Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation.
    Dey BR; McAfee S; Colby C; Cieply K; Caron M; Saidman S; Preffer F; Shaffer J; Tarbell N; Sackstein R; Sachs D; Sykes M; Spitzer TR
    Br J Haematol; 2005 Feb; 128(3):351-9. PubMed ID: 15667537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies.
    Porter DL; Connors JM; Van Deerlin VM; Duffy KM; McGarigle C; Saidman SL; Leonard DG; Antin JH
    J Clin Oncol; 1999 Apr; 17(4):1234. PubMed ID: 10561184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.